Eric Paul Wehrenberg-Klee, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Yttrium Radioisotopes | 6 | 2021 | 93 | 2.550 |
Why?
|
Carcinoma, Hepatocellular | 8 | 2021 | 2214 | 1.530 |
Why?
|
Cryosurgery | 4 | 2024 | 453 | 1.200 |
Why?
|
Liver Neoplasms | 10 | 2021 | 4253 | 1.140 |
Why?
|
Embolization, Therapeutic | 6 | 2021 | 1392 | 0.790 |
Why?
|
Chemoembolization, Therapeutic | 1 | 2021 | 129 | 0.740 |
Why?
|
Immunotherapy | 8 | 2024 | 4445 | 0.710 |
Why?
|
Cancer Vaccines | 1 | 2022 | 1023 | 0.500 |
Why?
|
Radiography, Interventional | 2 | 2019 | 1095 | 0.500 |
Why?
|
Positron-Emission Tomography | 8 | 2021 | 6234 | 0.480 |
Why?
|
Granzymes | 3 | 2020 | 271 | 0.450 |
Why?
|
Neoplasms, Experimental | 1 | 2016 | 1276 | 0.370 |
Why?
|
Molecular Imaging | 1 | 2016 | 828 | 0.330 |
Why?
|
Receptor, erbB-3 | 2 | 2021 | 142 | 0.330 |
Why?
|
Neoplasms | 5 | 2024 | 21683 | 0.320 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2016 | 1660 | 0.320 |
Why?
|
Patient Selection | 2 | 2019 | 4215 | 0.300 |
Why?
|
Combined Modality Therapy | 5 | 2024 | 8642 | 0.290 |
Why?
|
Catheter Ablation | 3 | 2021 | 2758 | 0.280 |
Why?
|
Microspheres | 3 | 2021 | 777 | 0.240 |
Why?
|
Glycolates | 1 | 2023 | 40 | 0.240 |
Why?
|
Portal Pressure | 1 | 2020 | 62 | 0.190 |
Why?
|
Adjuvants, Immunologic | 2 | 2023 | 1000 | 0.190 |
Why?
|
Radiation Pneumonitis | 1 | 2020 | 104 | 0.180 |
Why?
|
Technology | 1 | 2022 | 305 | 0.180 |
Why?
|
Radiopharmaceuticals | 2 | 2020 | 2645 | 0.180 |
Why?
|
Tissue Distribution | 2 | 2021 | 2327 | 0.170 |
Why?
|
Liver Transplantation | 2 | 2021 | 2119 | 0.170 |
Why?
|
Kidney Failure, Chronic | 1 | 2011 | 2538 | 0.170 |
Why?
|
Genes, cdc | 1 | 2018 | 116 | 0.160 |
Why?
|
Hypertension, Portal | 1 | 2020 | 220 | 0.160 |
Why?
|
Kidney Neoplasms | 2 | 2013 | 4262 | 0.160 |
Why?
|
Antineoplastic Agents | 1 | 2021 | 13695 | 0.160 |
Why?
|
Ablation Techniques | 1 | 2021 | 249 | 0.150 |
Why?
|
Cell Line, Tumor | 6 | 2021 | 16689 | 0.150 |
Why?
|
Liver Function Tests | 1 | 2019 | 528 | 0.150 |
Why?
|
Safety | 1 | 2021 | 1186 | 0.140 |
Why?
|
Carcinoma, Renal Cell | 1 | 2011 | 3143 | 0.140 |
Why?
|
Immunologic Factors | 2 | 2022 | 1580 | 0.140 |
Why?
|
Angiography | 1 | 2020 | 1639 | 0.130 |
Why?
|
Hepatectomy | 1 | 2018 | 550 | 0.120 |
Why?
|
Quinazolines | 1 | 2021 | 1356 | 0.120 |
Why?
|
Salvage Therapy | 1 | 2021 | 1275 | 0.120 |
Why?
|
Breast Neoplasms | 1 | 2021 | 20822 | 0.120 |
Why?
|
Treatment Outcome | 10 | 2021 | 63114 | 0.110 |
Why?
|
Octreotide | 1 | 2013 | 145 | 0.110 |
Why?
|
Receptors, Somatostatin | 1 | 2013 | 129 | 0.110 |
Why?
|
Brachytherapy | 1 | 2021 | 1248 | 0.110 |
Why?
|
Radiotherapy Dosage | 1 | 2019 | 2879 | 0.100 |
Why?
|
Receptor, erbB-2 | 1 | 2021 | 2416 | 0.100 |
Why?
|
Lung | 2 | 2020 | 9856 | 0.100 |
Why?
|
Humans | 24 | 2024 | 744343 | 0.100 |
Why?
|
Intestinal Neoplasms | 1 | 2013 | 319 | 0.100 |
Why?
|
Colonic Neoplasms | 2 | 2018 | 2541 | 0.090 |
Why?
|
Lymphoma | 1 | 2018 | 1877 | 0.090 |
Why?
|
Neuroendocrine Tumors | 1 | 2013 | 594 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 3 | 2018 | 20129 | 0.070 |
Why?
|
Lymph Nodes | 1 | 2018 | 3474 | 0.070 |
Why?
|
Mice | 8 | 2021 | 81183 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2021 | 5172 | 0.070 |
Why?
|
Peptides | 1 | 2018 | 4409 | 0.070 |
Why?
|
Gallium Radioisotopes | 2 | 2018 | 178 | 0.070 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2013 | 1524 | 0.060 |
Why?
|
Hypnotics and Sedatives | 1 | 2013 | 1162 | 0.060 |
Why?
|
Surgery, Computer-Assisted | 1 | 2013 | 1018 | 0.060 |
Why?
|
Glomerular Filtration Rate | 1 | 2011 | 2170 | 0.060 |
Why?
|
Retrospective Studies | 8 | 2021 | 77449 | 0.060 |
Why?
|
Pain, Postoperative | 1 | 2013 | 1643 | 0.050 |
Why?
|
Animals | 8 | 2021 | 168757 | 0.050 |
Why?
|
Cell Proliferation | 2 | 2016 | 10481 | 0.050 |
Why?
|
Female | 10 | 2021 | 380194 | 0.050 |
Why?
|
Technetium Tc 99m Aggregated Albumin | 1 | 2020 | 67 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2021 | 6773 | 0.050 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 14722 | 0.050 |
Why?
|
Liver Circulation | 1 | 2020 | 164 | 0.050 |
Why?
|
Male | 9 | 2021 | 350118 | 0.050 |
Why?
|
Aged, 80 and over | 5 | 2020 | 57776 | 0.040 |
Why?
|
Microwaves | 1 | 2021 | 191 | 0.040 |
Why?
|
Retreatment | 1 | 2020 | 610 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2016 | 9274 | 0.040 |
Why?
|
Somatostatin | 1 | 2020 | 459 | 0.040 |
Why?
|
Melanoma | 1 | 2017 | 5510 | 0.040 |
Why?
|
Prognosis | 2 | 2016 | 29063 | 0.040 |
Why?
|
Retroperitoneal Space | 1 | 2018 | 176 | 0.040 |
Why?
|
Pulmonary Circulation | 1 | 2020 | 739 | 0.040 |
Why?
|
Reproducibility of Results | 1 | 2016 | 19905 | 0.040 |
Why?
|
Middle Aged | 8 | 2021 | 213383 | 0.040 |
Why?
|
Aged | 7 | 2021 | 163280 | 0.040 |
Why?
|
Biotin | 1 | 2018 | 254 | 0.040 |
Why?
|
Prospective Studies | 1 | 2021 | 53288 | 0.040 |
Why?
|
Radiometry | 1 | 2021 | 800 | 0.030 |
Why?
|
Biomarkers, Pharmacological | 1 | 2017 | 162 | 0.030 |
Why?
|
Pelvis | 1 | 2018 | 730 | 0.030 |
Why?
|
Chemical Fractionation | 1 | 2013 | 65 | 0.030 |
Why?
|
Adult | 5 | 2020 | 214055 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2020 | 15076 | 0.030 |
Why?
|
Droperidol | 1 | 2013 | 21 | 0.030 |
Why?
|
Radiation Dosage | 1 | 2020 | 1928 | 0.030 |
Why?
|
Solubility | 1 | 2013 | 1085 | 0.030 |
Why?
|
Midazolam | 1 | 2013 | 270 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2018 | 2924 | 0.020 |
Why?
|
Liver Cirrhosis | 1 | 2020 | 1863 | 0.020 |
Why?
|
Contrast Media | 1 | 2023 | 5300 | 0.020 |
Why?
|
Hemodynamics | 1 | 2020 | 4199 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2021 | 6538 | 0.020 |
Why?
|
Fentanyl | 1 | 2013 | 410 | 0.020 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2017 | 1821 | 0.020 |
Why?
|
Radionuclide Imaging | 1 | 2013 | 2031 | 0.020 |
Why?
|
Risk Assessment | 2 | 2021 | 23338 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2019 | 5078 | 0.020 |
Why?
|
Cohort Studies | 2 | 2021 | 40561 | 0.020 |
Why?
|
Time Factors | 2 | 2021 | 40075 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2020 | 3586 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2016 | 6386 | 0.020 |
Why?
|
Tumor Burden | 1 | 2013 | 1915 | 0.020 |
Why?
|
Mice, Nude | 1 | 2013 | 3689 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2016 | 2942 | 0.020 |
Why?
|
Protein Binding | 1 | 2018 | 9386 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2013 | 6314 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2013 | 3557 | 0.020 |
Why?
|
Biopsy | 1 | 2017 | 6756 | 0.020 |
Why?
|
Risk Factors | 2 | 2021 | 72290 | 0.010 |
Why?
|
Pain Measurement | 1 | 2013 | 3420 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2013 | 10943 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2018 | 18029 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2021 | 39050 | 0.010 |
Why?
|
Rats | 1 | 2013 | 24260 | 0.010 |
Why?
|
Young Adult | 1 | 2018 | 56430 | 0.010 |
Why?
|
Child | 1 | 2018 | 77709 | 0.010 |
Why?
|
Adolescent | 1 | 2018 | 85781 | 0.010 |
Why?
|